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Abstract
Eukaryotic cytochrome oxidases are composed of up to 13 subunits, of which three, subunits 1, 2 and 3, are mitochondrially encoded. In
this study, yeast mutants were used to investigate the role of subunits 1 and 3 domains on the enzyme assembly. Mutation S203L in subunit 3
which abolished the respiratory growth, decreased cytochrome oxidase content, as measured by optical spectroscopy and immunodetection.
Secondary mutations in subunits 1 and 3 restored (partly) the enzyme level. Two reversions reintroduced residues with a hydroxyl group at
the primary mutation site (S203T) or in a subunit 3 transmembrane helix close to subunit 1 (G104S). These residues may be involved in
hydrogen bonding which strengthen subunits 1–3 interaction. Two other reversions (A224V and Q137K) are located in P-side loops in
subunit 1, which may be involved in the enzyme assembly. A mutation in residue A224 has been reported in a family presenting with
encephalomyopathy. Surprisingly, the introduction of the ‘human’ mutation A224S and of a more drastic change A224F had no effect on the
yeast enzyme. This might be explained by differences in local folding in the two enzymes. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Mitochondrial cytochrome oxidase is a complex multi-
meric enzyme with up to 13 subunits of dual genetic origin.
Three subunits (subunits 1, 2 and 3) are mitochondrially
encoded, are homologous to subunits of the bacterial termi-
nal oxidases and form the catalytic core of the enzyme.
Subunit 2 forms part of the docking site for cytochrome c
and binds CuA, the first electron acceptor. Subunit 1 binds
haem a and the binuclear centre (haem a3 CuB), the site of
oxygen reduction. Subunit 3 has no redox centre and is
involved in the assembly or stability of the complex.
Study of the assembly of cytochrome oxidase in cultured
human cells has identified two assembly intermediates of
the enzyme [1]. The first contains subunits 1 and 4. Subunits
2 and 3 are then added, together with subunits 5a, 5b, 6b, 6c,
7a or 7b. Finally, subunits 6a and 7a or 7b are incorporated.
Study of the mutant form harbouring the M29K mutation in
a transmembrane helix of subunit 2 showed that the muta-
tion arrested the assembly after the first intermediate (sub-
units 1 and 4) and that the haem a3 was dramatically
decreased. That suggested that the association of subunits
1 and 2 is necessary for the binding of haem a3 [2]. It has
been shown that in Rhodobacter sphaeroides cytochrome
oxidase, subunit 1 expressed in the absence of subunits 2
and 3 genes contained haem a but not haem a3. It is
therefore likely that the insertion of haem a3 requires the
association of subunits 1 and 2. Subunit 3 does not seem
required for the binding of the metal centres [3].
In this paper, we used yeast mutants to explore the role of
subunit domains on enzyme assembly. We characterized the
effect of mutation S203L in subunit 3 on enzyme assembly
and showed that the mutation decreased cytochrome oxidase
level and inhibited respiratory growth. Revertants were
selected and the secondary mutations (reversions) which
restored partly the respiratory competence were identified.
The reversions were located in subunits 1 and 3 of cyto-
chrome oxidase and interestingly, in regions of the proteins
where human disease mutations have been found.
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2. Materials and methods
2.1. Introduction of site-directed mutations in mitochond-
rially encoded COX1
The yeast strains and media used in this study were
described previously [4,5]. Site-directed mutagenesis, biol-
istic transformation of mitochondria, screening of the trans-
formants and replacement of the wild-type COX1 gene by
the mutated form in the mitochondrial genome (mtDNA)
were performed as described in Ref. [5].
2.2. Spectrophotometric measurements and quantitation of
cytochrome oxidase
Difference spectra were generated by sequential scanning
of the same sample with a single beam instrument built in-
house. The difference spectra of cell suspensions were
obtained as followed: the cells, grown on YPD plates for
48 h, were resuspended in 5% Ficoll, 50 mM Tris–HCl (pH
7) at a concentration of around 180 mg of cells per milliliter.
The samples were oxidized with 0.025% H202 in presence
of 10 AM myxothiazol and a first spectrum was recorded.
The samples were then reduced by dithionite. A second
spectrum was taken. The data are presented as reduced
minus oxidized spectra. To remove distortions of the base-
lines, a quadratic baseline compensation was carried out on
the data as described in Ref. [6] using three wavelengths,
542, 575 and 630 nm.
Quantitation of cytochrome oxidase was based on the
haem a signal of the reduced minus oxidized spectra in the
visible region. Cytochrome oxidase content was estimated
by using an extinction coefficient (e) of 14 mM 1 cm 1 at
604(594+614)/2 nm [7]. Cytochrome c content was esti-
mated by using e= 18 mM 1 cm 1 at 550–542 nm.
2.3. Respiratory activity of cell suspensions
Oxygen consumption activity was measured in an oxy-
gen electrode. Cell suspensions were diluted to around
50 mg in 1 ml of 50 mM potassium phosphate, 150 mM
glucose, 2.5 AM carbonyl cyanide p-(trifluoromethoxy)
phenyl-hydrazone (FCCP) at pH 7 at 28 jC and the rate
of oxygen consumption recorded. The data are presented
as electron consumed per cytochrome oxidase per sec-
ond.
2.4. Determination of steady-state levels of subunits
Yeast strains were grown in YPD at 30 jC and harvested
at late log phase. Spheroplasts were prepared as described
[8], except that lyticase (Sigma) was used to digest the cell
walls. Aliquots of spheroplasts (0.1 g wet weight) were
lysed in 0.9 ml of 10% sodium dodecyl sulfate (SDS),
undissolved material was removed by centrifugation, and
50 Al of 0.5 M Tris–HCl (pH 6.8), 20 Al of 2-mercaptoe-
thanol, 120 Al of glycerol and a few grains of bromophenol
blue were added to each sample. Serial dilutions of the
wild-type sample were prepared in 10% SDS, 50 mM
Tris–HCl (pH 6.8), 2% 2-mercaptoethanol and 12% glyc-
erol. Equal volumes of the lysates and the dilution series
were resolved on 12.5% or 15% polyacrylamide gels
containing 5.8 M urea [9]. Gels were blotted onto poly-
vinylidine difluoride membranes and reacted with mouse
monoclonal antibodies [10]. The following monoclonal
antibodies raised against yeast proteins were used: 3F7
(anti-heat shock protein 60), 16G9-E6 (anti-porin), 11D8-
B7 (anti-COX1), 4B12-A5 (anti-COX2), DA5 (anti-
COX3), 1A12-A12 (anti-COX 4), 13E2-F5 (anti-COX5),
7E3 (anti-COX6a), 11D11-H6 (anti-COX6) and 20B5 (anti-
COX8). All antibodies were prepared in the laboratory of
Dr. R.A. Capaldi [10]. Immunoreactive polypeptides were
detected with the Renaissance Western Blot Chemilumi-
nescence Reagent Plus kit (NEN Life Science Products)
using horse radish peroxidase-conjugated anti-mouse anti-
bodies. Signals were measured by densitometry. Exposure
times of blots to pre-flashed Hyperfilm ECL film (Amer-
sham Pharmacia Biotech) were chosen such that all signals
were within the linear range.
3. Results and discussion
3.1. Genetic characterisation of the deficient mutation and
reversions, and generation of site-directed mutants
The respiratory growth deficient mutant S203L was
obtained by random mutagenesis described in Ref. [4].
The deficiency mutation was mapped in COX3 [4] and
sequenced. From this deficient strain, revertants (respiratory
growth competent clones) were selected on respiratory
medium. The mitochondrial reversions were identified as
in Refs. [11,12]. S203L, the primary mutation is located in
the top of transmembrane helix 6 of subunit 3 (Fig. 1), 3 A˚
from residue T218 at the top of helix 5 of subunit 1. Five
different reversions were observed: wild-type S203, a
change at the same position S203T and three second-site
reversions: G104S in subunit 3, and A224V and Q137K in
subunit 1. G104S is located in helix 3 of subunit 3, in the
interface with subunit 1. Q137K is in a P-side loop of
subunit 1. A224V is also in a P-side loop of subunit, close
to a subunit 3 loop. It is interesting to note that a mutation
in that residue A224S (A223S in human) has been
observed in association with disease [13]. To study further
the effect of mutations in residue A224 in subunit 1, we
used the biolistic method (Materials and Methods) to
introduce the following changes: A224V (reversion),
A224S (human mutation) and A224F. The replacement of
A224 by a bulky phenylalanine was expected to hinder the
folding of the subunits. The subunit 1 mutation Q137K was
also constructed to monitor the effect of the reversion
alone.
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3.2. Effect of the mutations on the respiratory function
3.2.1. Growth, respiratory activity and cytochrome oxidase
content
The effects of the mutations on the respiratory growth
competence, and on cytochrome oxidase content and activ-
ity in cells were monitored (Table 1). The mutation S203L
in subunit 3 abolished the respiratory growth. The cyto-
chrome oxidase content (based on reduced minus oxidized
spectrum) was decreased to 30% of the wild-type level
while the cytochrome c content was increased (Fig. 2). The
level of haem a3 based on the reduced plus cyanide minus
reduced spectra was identical to that based on the reduced
minus oxidised spectra (data not shown). The oxygen
consumption activity of the mutant cytochrome oxidase,
measured as described in Materials and Methods, was
similar to that of the wild-type enzyme (450+50 s1). It
seems therefore that the assembled enzyme in the mutant
was active but its amount in the cells was too low to support
the respiratory growth.
The replacement of S203L by a threonine restored a
wild-type level of enzyme (Fig. 2), and growth competence.
The second-site reversion in position 104 (G104S) restored
partially the respiratory growth (25% of the wild-type
growth rate). The level of cytochrome oxidase was
increased from 35% in the primary mutant to 60% in the
double mutant. The second-site reversions in subunit 1
(A224V and Q137K) had similar effect. Oxygen consump-
tion activity per cytochrome oxidase in the revertants was
similar to that of the wild type. The temperature sensitivity
of the respiratory growth competence was monitored (Table
1). In the revertant S203T, cytochrome oxidase content and
growth competence were similar to the wild type. In the
primary mutant S203L, the level of cytochrome oxidase was
further decreased to around 12% of that of the wild type.
The respiratory growth of the double mutants was abolished
at 37 jC. The cytochrome oxidase level in those strains was
decreased to 40–50% of that of the wild type.
It seems therefore that the minimum level of cytochrome
oxidase needed by these cells to grow on a respiratory
medium was above 0.5 nmol/g (40–50% of the wild-type
cytochrome oxidase content). A concentration of 0.6 nmol/g
allowed the cells to grow but at a significant lower rate. We
have already observed, using the same yeast strain (with
different mitochondrial mutations in cytochrome oxidase)
that changes in the respiratory activity affected strongly the
Fig. 1. Location of the mutated residues in cytochrome oxidase subunits 1 (dark grey) and 3 (light grey). The structure has been drawn from the co-ordinates of
the bovine enzyme [21]. The numbering is according to the yeast sequence. The comparison of the sequences of the subunits 1 and 3 region close to residue
A224 is shown in the boxes.
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respiratory growth competence. For instance, we showed
that the subunit 1 mutations E243D, I280T and M273T had
no effect on the enzyme content but decreased the catalytic
activity by 50–60%. This resulted in a decrease of the
respiratory growth rate by 60–70% [5]. It seems therefore
that there is a very limited buffering capacity in the
respiratory function in those strains.
Note that the secondary mutations A224Vand Q137K by
themselves had no deleterious effect on the respiratory
function.
3.2.2. Steady-state level of cytochrome oxidase subunits
To study further the effect of the subunit 3 mutation
S203L on the assembly of cytochrome oxidase, we moni-
tored the subunit steady-state levels in SDS-lysed sphero-
plasts of the mutant and compared them to those in wild
type and revertant S203L+A224V on immunoblots (Fig. 3).
Blots were developed with subunit-specific monoclonal
antibodies and signals were measured by densitometry. To
allow accurate quantification, mutant samples and serial
dilutions of wild-type samples were present on the same
blot. The signal obtained with antibodies against yeast porin
was used to correct for unequal loading. When signals
obtained with antibodies against yeast heat shock protein
60 were used for correction, the results were identical (not
shown).
The immunoblots showed that the S203L mutation had a
profound effect on the level of all cytochrome oxidase
subunits that were investigated. This confirms that the
mutation affects the assembly and/or stability of the com-
plex and suggests that unassembled subunits were rapidly
degraded by the AAA proteases (ATPases associated with
diverse cellular activities) of mitochondria [14,15]. Quanti-
fication of the signals on the blots indicated that the levels of
subunits 1, 2, 3, 5 and 6a were more affected (10–17% of
wild-type levels) than the levels of subunits 4, 6 and 8 (30–
50% of wild-type levels). In analogy to their mammalian
counterparts, the yeast subunits 4 and 6 are considered to be
extrinsic polypeptides located on the matrix side of the
enzyme complex, whereas all other subunits investigated on
the immunoblots of Fig. 3 span the membrane. Glerum and
Tzagoloff [16] have shown that in wild-type yeast mito-
chondria, disrupted by a brief sonic treatment, the subunits
of cytochrome oxidase were associated with the membrane
fraction. A small percentage of subunits 4 and 6, however,
was found in the soluble fraction. In assembly defective
cytochrome oxidase mutants, they observed a shift of
subunits 4 and 6 to the soluble fraction. These observations
suggest that subunits 4 and 6 are less prone to proteolytic
degradation than other cytochrome oxidase subunits and in
absence of assembly, significant pools of unassembled
subunits 4 and 6 are present in the mitochondrial matrix.
Apparently, also subunit 8, which was not investigated with
Fig. 2. Optical spectra of wild-type and mutant cells. The optical spectra of
wild-type and mutant cell suspensions were monitored as described in
Materials and methods. The data are presented as reduced minus oxidised
spectra. Quantitation of cytochrome oxidase was based on the haem a
signal at 604 (594 + 614)/2. The arrows indicate 594 and 614 nm.
Table 1









Cells grown at 28 jC
Wild type 100 5.5 1
su3S203L ndc 11 0.3
su3S203T 100 6 0.95
su3S203L+su3G104S 25 9 0.6
su3S203L+su1A224V 30 9 0.7
su3S203L+su1Q137K 30 7 0.6
su1A224V 100 6 1
su1A224S 100 6 1.2
su1A224F 100 7 0.9
su1Q137K 100 5 0.9
Cells grown at 37 jC
Wild type 100 5.5 1.2
su3S203L ndc 11 0.15
su3S203T 100 8.5 1.3
su3S203L+su1A224V ndc 12 0.5
su3S203L+su1Q137K ndc 11 0.5
a The cells were incubated in YG medium and the cell density of the
cultures was monitored at various times. The data are presented as
percentage of the wild-type growth rate.
b Cytochrome oxidase (CcO) and cytochrome c (Cyt.c) contents are
estimated as described in Materials and Methods and are given in
nanomoles per gram of cells.
c No growth could be detected.
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a subunit specific antiserum by Glerum and Tzagoloff [16],
is relatively stable in the absence of assembly.
Quantitation of cytochrome oxidase based on haem a
signal showed a higher level of enzyme (30% of the wild-
type signal) than the level estimated by immunodetection
(10–17%). The optical spectra were performed directly on
cell suspensions immediately after harvesting the cells while
the immunoblots required the preparation of spheroplasts.
The mild treatment might decrease the level of unstable
cytochrome oxidase in the mutant cells. Indeed this de-
creased enzyme level in spheroplasts was confirmed by op-
tical spectroscopy (not shown).
Subunit levels in the S203L+su1A224V revertant were
higher (70–100% of wild-type levels) which confirmed that
the second site A224V mutation was able to restore the
assembly and/or stability defect caused by the S203L
mutation. However, development with antibodies against
subunit 2 revealed a minor band migrating slightly faster
than subunit 2, which was stronger in the revertant than in
wild-type spheroplasts. This minor band most likely repre-
Fig. 3. Steady-state subunit levels in spheroplasts. Steady-state levels in the S203L mutant and the S203L+su1A224V revertant were compared to serial
dilutions of the wild-type strain on Western blots developed with subunit specific monoclonal antibodies as described in Materials and Methods.
B. Meunier, J.-W. Taanman / Biochimica et Biophysica Acta 1554 (2002) 101–107 105
sents a proteolytic degradation product of subunit 2 and
suggests that proteolytic degradation of subunit 2 is still
slightly higher in the revertant than in the wild-type strain.
3.3. Compensation of the assembly defect
As shown above, mutation S203L in subunit 3 resulted in
a lower cytochrome oxidase content and abolished the
growth of the mutant strain on respiratory substrate. The
introduction of a threonine at that same position restored the
enzyme content to wild-type level. It is therefore likely that
a polar residue with a hydroxyl group is needed at that
position. In the atomic structure of the bovine enzyme,
residue 203 (yeast numbering) is located at the P side end
of helix 6, approximately 3 A˚ from threonine 218 of subunit
1. It is possible that these residues or their surrounding are
involved in a hydrogen-binding network which stabilises the
assembly of subunits 1 and 3.
The assembly of the enzyme was partly restored by a
second mutation G104S in subunit 3. This residue is located
far from the primary site (10 A˚) but is also close to subunit 1
transmembrane helix. The gain of the polar residue G104S
may allow the formation of new hydrogen bond, which
could partly compensate for the loss of the hydrogen-bind-
ing S203, and strengthen the assembly with subunit 1. A
five-amino residue deletion in that same region of helix 3
(DF102–106 yeast numbering) has been observed in a
patient with recurrent myoglobinuria [17]. This mutation
abolishes completely the enzyme assembly both in human
and yeast cells [5,18].
Two long-distance (10–15 A˚) reversions have been
found in subunit 1, A224V and Q137K. They are located
in loop regions at the P side of the membrane. Q137 (L136
in bovine) has no close contact with other subunit residues.
At 3 A˚ from Q137, a deficiency mutation S140L which
affects the assembly of the complex has been previously
observed [19]. That suggests a role for that domain in the
assembly process or stabilisation of the complex. A224
(A223 in bovine) is close to residues of subunit 3 (Fig. 1).
It is possible that the introduction of the bulkier residue
valine alters slightly the local fold of the region, strengthens
the assembly of subunits 1 and 3 and compensates partly the
complex destabilisation induced by the primary mutation
S203L. As described below, two other changes have been
introduced in position 224 (A224S and F). These mutations
were not able to compensate the respiratory growth defect
caused by S203L. In a previous study on mutations in
cytochrome oxidase subunits 1 and 2 [19], we showed that
reversions which compensate assembly defect could be
located up to 30 A˚ from the primary mutation. The muta-
tions (deficiency and compensation) seemed to form a
pattern. They were located near the subunits interface and
near the metal binding sites. The long-distance effect of the
secondary mutations could be due to slight changes in the
folding which strengthen the assembly of the core subunits
1, 2 and 3.
3.4. Effect of mutations of A224 in subunit 1, in human and
in yeast
A mutation at that same position 224 in subunit 1
(A223S in human) has been observed in a family with
diverse clinical features ranging from myopathy to a
multisystem disorder [13]. In muscle with highest mu-
tation load (91%), cytochrome oxidase activity was de-
creased to 25% of the control. We could postulate that the
introduction of a polar serine would hinder the proper
folding of these regions in the human enzyme and
destabilize the assembly of subunits 1 and 3. The decrease
in cytochrome oxidase activity observed in the muscle
from the patient would be caused by a lower level of
assembled enzyme, and not by a decreased catalytic turn-
over of the enzyme. It is unlikely that the mutation affects
the enzymatic activity since it is located far from the
catalytic domain.
Because of the pathogenic effect of the A224S mutation
in humans, it seemed particularly interesting to study the
effect of mutations at that position in yeast. Yeast and
human cytochrome oxidases are highly similar. The sequen-
ces of the mitochondrially encoded subunits are 40–45%
identical. In addition, designed mutations, such as ‘disease’
mutations, can be introduced into yeast mtDNA since yeast
is amenable to mitochondrial transformation. The mutants
can then be used as model to study the effect of these
mutations on the enzyme assembly and activity. In a
previous study [5], we characterised, in yeast, four ‘human’
mutations associated with disease: M273T, I280T and
G317S, located in or near the K-channel in subunit 1 and
the short in-frame deletion DF102–106 in subunit 3. We
showed that the mutations introduced in yeast caused
identical effects to those reported in human cells. The
subunit 3 mutation was highly deleterious and abolished
the enzyme assembly. G317S had no effect on the respira-
tory function. M273T and I280T were mildly deleterious,
decrease cytochrome oxidase activity and slightly perturb
the binuclear centre properties.
In this work, we replaced A224 by valine (reversion
mutation), serine (human mutation) and phenylalanine (to
increase the possible folding hindrance). Surprisingly, the
mutations had no effect on the respiratory growth compe-
tence and cytochrome oxidase content (Table 1). As
described above, residue A224 is located in a region
forming a loop between helices 5 and 6 of subunit 1. In
the bovine enzyme, it is close to a loop between helices 3
and 4 of subunit 3. The closest subunit 3 residue is residue
119 (111 in human or bovine) located 5 A˚ from A224. The
sequences of the loops are different in yeast and human (or
bovine) (Fig. 1). Therefore, we could postulate that in the
yeast enzyme, that region is less packed so that the muta-
tions have no effect. The loop region around A224 may be
flexible enough to move and accommodate a bulky residue
such as phenylalanine, without any effect on the enzyme
assembly. The introduction of the polar residue serine could
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be compensated by rearrangement of the solvent. We have
already described a similar mutation. The mutation G317S
in subunit 1 has been found in fibroblasts from a patient
presenting with lactic acidaemia and cytochrome oxidase
deficiency. Residue G317 is a highly conserved residue
located next to T316, which is part of the K-channel. It
could have been expected that the replacement of G317 by
serine might perturb T316 and affect the catalytic activity.
But it was shown that the mutation had no effect on human
enzyme and that the defect was caused by a mutation in the
nuclear SURF1 gene instead [20]. When introduced in
yeast, the mutation similarly had no effect on yeast cyto-
chrome oxidase [5]. It could also be suggested that the
change was compensated by the rearrangement of the net-
work of water molecules in K-channel. The atomic reso-
lution of the yeast enzyme structure may explain the
apparent discrepancy between the effects of the ‘loop’
mutation A224S in yeast and humans.
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